TQH3906
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
January 03, 2025
TQH3906-Ib-01: Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
(clinicaltrials.gov)
- P1 | N=116 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
September 20, 2024
TQH3906-II-01: Treatment of Moderate to Severe Plaque Psoriasis
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatology • Immunology • Psoriasis
August 07, 2024
Treatment of Moderate to Severe Plaque Psoriasis
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P2 trial • Dermatology • Immunology • Psoriasis
March 04, 2024
A Clinical Trial of TQH3906 Capsules in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=76 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatology • Immunology • Psoriasis
January 30, 2024
A Clinical Trial of TQH3906 Capsules in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=76 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial • Dermatology • Immunology • Psoriasis
1 to 5
Of
5
Go to page
1